NEW YORK (GenomeWeb) – Biocept said today that it will collaborate with University of Minnesota researcher Shilpa Gupta on a study evaluating the company's Target Selector liquid biopsy platform for detection of PD-L1 and androgen receptor (AR) expression in bladder and prostate cancer patients.
Biocept launched its circulating tumor cell-based PD-L1 assay in May and its AR expression test in January.
Gupta, who is a principal investigator in several clinical trials evaluating targeted and immunotherapeutic drugs for prostate and bladder cancers, said in a statement that the tissue biopsies and cystoscopy standardly used for these patients are invasive and can be expensive.
"Biocept's liquid biopsy tests have shown high concordance with tissue biopsies in detecting genetic [alterations] associated with multiple cancers, and this study is aimed at providing additional clinical support for the use of these tests specifically in bladder and prostate cancers," he added.